O-acetyl-(R)-carnitineWhat was measured
Measured, with no finding
226 endpoints
Show what was measuredHide what was measured
ataxia clinical score, some symptoms
decreases
After the trial, we observed a statistically significant improvement of some symptoms and a slow progression of the disease in both groups of patients
PMID 10803803 · one of two readings recorded this
blood urea nitrogen (BUN), serum ammonia, Glasgow Scale neurological findings and EEG grade in cirrhotic hepatic coma, LAC versus placebo
Not recorded as a finding: the direction is carried only as a signed number
Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment.
PMID 17080254 · one of two readings recorded this
BUN
unclear
Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment
PMID 17080254 · one of two readings recorded this
improved EEG grade (subjects)
increases
In the other group we observed an improvement of neurological findings and of EEG grade in 10 and 8 subjects, respectively
PMID 17080254 · one of two readings recorded this
improved neurological findings (subjects)
increases
In the other group we observed an improvement of neurological findings and of EEG grade in 10 and 8 subjects, respectively
PMID 17080254 · one of two readings recorded this
neurological findings (Glasgow Scale)
increases
Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment
PMID 17080254 · one of two readings recorded this
patients improving from grade 4 to grade 3
increases
Noteworthily, seven (54%) patients went from grade 4 down to grade 3, and one from grade 4 down to grade 1
PMID 17080254 · one of two readings recorded this
serum ammonia
unclear
Statistically significant differences in neurological findings, as evaluated by the Glasgow Scale, as well as in ammonia serum levels and BUN were found following LAC treatment
PMID 17080254 · one of two readings recorded this
hyperactivity on the Conners' Global Index Parents; social behaviour on the Vineland Adaptive Behavior Scale, in FXS boys with ADHD over one year
decreases
Not recorded as a finding: this platform holds no node for the endpoint
However, we observed a stronger reduction of hyperactivity and improvement of social behavior in patients treated with LAC, compared with the placebo group, as determined by the Conners' Global Index Parents and the Vineland Adaptive Behavior Scale.
PMID 18286595 · one of two readings recorded this
hyperactivity on the Conners' Global Index Parents; social behaviour on the Vineland Adaptive Behavior Scale
decreases, stronger reduction of hyperactivity with LAC than placebo; no numeric estimate stated
Not recorded as a finding: this platform holds no node for the endpoint
However, we observed a stronger reduction of hyperactivity and improvement of social behavior in patients treated with LAC, compared with the placebo group, as determined by the Conners' Global Index Parents and the Vineland Adaptive Behavior Scale.
PMID 18286595 · one of two readings recorded this
Hyperactivity
decreases
However, we observed a stronger reduction of hyperactivity and improvement of social behavior in patients treated with LAC, compared with the placebo group, as determined by the Conners' Global Index Parents and the Vineland Adaptive Behavior Scale
PMID 18286595 · one of two readings recorded this
Social behavior
increases
However, we observed a stronger reduction of hyperactivity and improvement of social behavior in patients treated with LAC, compared with the placebo group, as determined by the Conners' Global Index Parents and the Vineland Adaptive Behavior Scale
PMID 18286595 · one of two readings recorded this
EEG frequency
increases, p = 0.001
a significant improvement of EEG cps/s: 2.70 versus 0.6 P<0.001
PMID 19357525 · one of two readings recorded this
serum ammonia levels (mumol); Glasgow Coma Scale score; EEG cps/s; blood urea nitrogen within-arm only
decreases, 41.20 versus 10.40 mumol
Not recorded as a finding: this platform holds no node for the endpoint
After 60 min of the study period, the LAC+BCAA treated patients compared with BCCA treated showed a significant decrease of ammonia serum levels: 41.20 versus 10.40 mumol P<0.05.
PMID 19357525 · one of two readings recorded this
serum ammonia (mumol), Glasgow Scale neurological score, EEG cps/s, blood urea nitrogen in cirrhotic hepatic coma; LAC+BCAA versus BCAA, both intravenous
decreases, 41.20 versus 10.40 mumol
Not recorded as a finding: this platform holds no node for the endpoint
After 60 min of the study period, the LAC+BCAA treated patients compared with BCCA treated showed a significant decrease of ammonia serum levels: 41.20 versus 10.40 mumol P<0.05.
PMID 19357525 · one of two readings recorded this
Serum ammonia
decreases, p = 0.01
a significant decrease of ammonia serum levels: 63.30 versus 27.00 mumol P<0.01
PMID 19357525 · one of two readings recorded this
Serum ammonia
decreases, p = 0.05
After 60 min of the study period, the LAC+BCAA treated patients compared with BCCA treated showed a significant decrease of ammonia serum levels: 41.20 versus 10.40 mumol P<0.05
PMID 19357525 · one of two readings recorded this
Insulin sensitivity (HOMA-IS) after therapy versus controls
no effect
nonstatistically different than controls after therapy (0.72+/-0.49 vs. 0.78+/-0.42)
PMID 19598076 · one of two readings recorded this
Insulin sensitivity (HOMA-IS)
decreases
Insulin sensitivity was significantly lower prior (HOMA-IS 0.56+/-0.30)
PMID 19598076 · one of two readings recorded this
intramyocellular triglyceride content of the soleus, (1)H NMR spectroscopy
decreases, p = 0.03
Not recorded as a finding: this platform holds no node for the endpoint
After this therapy, in HIV-1 patients, the IMCL content of the soleus had significantly decreased (p=0.03).
PMID 19598076 · one of two readings recorded this
intramyocellular triglyceride (IMCL) content of the soleus, (1)H NMR spectroscopy
decreases, p = 0.03
Not recorded as a finding: this platform holds no node for the endpoint
After this therapy, in HIV-1 patients, the IMCL content of the soleus had significantly decreased (p=0.03).
PMID 19598076 · one of two readings recorded this
Intramyocellular triglyceride (IMCL) content of the soleus
decreases, p = 0.03
After this therapy, in HIV-1 patients, the IMCL content of the soleus had significantly decreased (p=0.03)
PMID 19598076 · one of two readings recorded this
Percentage of fat in the legs
increases, p = 0.05
the percentage of fat in the legs increased (p=0.05)
PMID 19598076 · one of two readings recorded this
Plasma free fatty acids
decreases, p = 0.05
Plasma FFAs (0.79+/-0.31 to 0.64+/-0.25; p<0.05)
PMID 19598076 · one of two readings recorded this
Respiratory quotient (lipid oxidation, indirect calorimetry)
decreases, p = 0.03
Respiratory Quotient (0.83+/-0.18 to 0.72+/-0.16; p<0.03) also decreased
PMID 19598076 · one of two readings recorded this
degree of improvement, selegiline versus L-acetylcarnitine
unclear
The marked between-group differences demonstrate that, at the dosage used, selegiline was far more effective than L-acetylcarnitine with respect to the degree of improvement
PMID 2121359 · one of two readings recorded this
global cognitive function (processing, storage and retrieval of information)
increases
selegiline therapy led to a global improvement in the capacity for the processing, storage, and retrieval of given information
PMID 2121359 · one of two readings recorded this
psychometric battery (information processing, storage and retrieval, verbal fluency, visuospatial abilities) in mild-to-moderate Alzheimer-type disorders, selegiline vs L-acetylcarnitine
selegiline far more effective than L-acetylcarnitine; no LAC-vs-untreated estimate
Not recorded as a finding: the comparison was against another active treatment
The marked between-group differences demonstrate that, at the dosage used, selegiline was far more effective than L-acetylcarnitine with respect to the degree of improvement.
PMID 2121359 · one of two readings recorded this
verbal fluency and visuospatial abilities
increases
Improvements in verbal fluency and visuospatial abilities were also noted
PMID 2121359 · one of two readings recorded this
Beck Depression Inventory score
decreases
Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects
PMID 2205455 · one of two readings recorded this
behavioural aspects (Sandoz Clinical Assessment--Geriatric)
unclear
Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects
PMID 2205455 · one of two readings recorded this
depressive symptoms on the Hamilton Rating Scale for Depression and the Beck Depression Inventory, LAC vs placebo, elderly patients
decreases, decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory; no numeric estimate
Not recorded as a finding: the supporting sentence never names the compound
Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects.
PMID 2205455 · one of two readings recorded this
Hamilton Rating Scale for Depression and Beck Depression Inventory scores in elderly depressed patients, LAC 500 mg three times daily versus placebo
decreases
Not recorded as a finding: the supporting sentence never names the compound
Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects.
PMID 2205455 · one of two readings recorded this
Hamilton Rating Scale for Depression score
decreases
Relief of depressive symptomatology is expressed by decreased scores in the Hamilton Rating Scale for Depression and Beck Depression Inventory and by beneficial effects with regard to behavioural aspects
PMID 2205455 · one of two readings recorded this
Hyperactive behaviour, parents' assessment
decreases, n = 17
Parents' assessments favoured LAC in one study (MD -0.57, 95% CI -0.94 to -0.19, n = 17; low-quality evidence)
PMID 25985235 · one of two readings recorded this
Hyperactive behaviour, parents' assessment
no effect, n = 51
but not in the other (MD -2.80, 95% CI -7.61 to 2.01, n = 51; low-quality evidence)
PMID 25985235 · one of two readings recorded this
hyperactive behaviour, teacher-rated Conners' Abbreviated Parent-Teacher Questionnaire
no effect, MD 0.50, 95% CI -5.08 to 6.08, n = 51
Not recorded as a finding: this platform holds no node for the endpoint
In one study, teachers' assessments of the children found no clear evidence of a difference (mean difference (MD) 0.50, 95% confidence interval (CI) -5.08 to 6.08, n = 51; low-quality evidence).
PMID 25985235 · one of two readings recorded this
Hyperactive behaviour, teachers' assessment
no effect, n = 51
teachers' assessments of the children found no clear evidence of a difference (mean difference (MD) 0.50, 95% confidence interval (CI) -5.08 to 6.08, n = 51; low-quality evidence)
PMID 25985235 · one of two readings recorded this
Verbal and non-verbal intellectual functioning
no effect
The authors did not provide detailed data on those results but said that they found no important differences between treatment and placebo
PMID 25985235 · one of two readings recorded this
Vineland Adaptive Behavior composite
no effect, n = 51
one study reported no clear evidence of a difference in Vineland Adaptive Behavior composite scores (MD 8.20, 95% CI -0.02 to 16.42, n = 51; low-quality evidence)
PMID 25985235 · one of two readings recorded this
Vineland Adaptive Behavior socialisation domain
increases, n = 51
results in the socialisation domain favoured LAC (MD 11.30, 95% CI 2.52 to 20.08, n = 51; low-quality evidence)
PMID 25985235 · one of two readings recorded this
Body mass index
BMI, kg/m2 | 30.0 ± 4.8 | 30.1 ± 5.0 | 30.0 ± 5.1 | 30.0 ± 5.2
PMID 29696241 · one of two readings recorded this
Body mass index
BMI, kg/m2 | 30.0 ± 4.8 | 30.1 ± 5.0 | 30.0 ± 5.1 | 30.0 ± 5.2
PMID 29696241 · one of two readings recorded this
HDL cholesterol
no effect
HDL cholesterol, mg/dL | 45.0 ± 13.5 | 43.5 ± 14.0 | 44.9 ± 12.0 | 43.3 ± 12.4 a
PMID 29696241 · one of two readings recorded this
HDL cholesterol
decreases, p = 0.0174
total and HDL cholesterol significantly increased and decreased from 155.7 ± 33.7 mg/dL to 161.3 ± 31.6 mg/dL (P = 0.0164) and from 44.9 ± 12.0 mg/dL to 43.3 ± 12.4 mg/dL (P = 0.0174)
PMID 29696241 · one of two readings recorded this
HOMA-IR
no effect
Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2)
PMID 29696241 · one of two readings recorded this
HOMA-IR
decreases, p = 0.0251
from 3.1 (2.0 to 5.7) to 2.6 (1.7 to 4.8) (P = 0.0251) and from 3.3 (2.1 to 5.1) to 2.9 (1.7 to 5.2) (P = 0.0267)
PMID 29696241 · one of two readings recorded this
HOMA-IR
decreases, p = 0.0267
from 3.1 (2.0 to 5.7) to 2.6 (1.7 to 4.8) (P = 0.0251) and from 3.3 (2.1 to 5.1) to 2.9 (1.7 to 5.2) (P = 0.0267)
PMID 29696241 · one of two readings recorded this
LDL cholesterol
LDL cholesterol, mg/dL | 101.5 ± 27.3 | 101.3 ± 22.8 | 103.0 ± 27.6 | 102.4 ± 22.8 | 84.9 ± 25.4 | 86.5 ± 27.0 | 80.0 ± 19.3 | 87.3 ± 24.0 b
PMID 29696241 · one of two readings recorded this
LDL cholesterol
LDL cholesterol, mg/dL | 101.5 ± 27.3 | 101.3 ± 22.8 | 103.0 ± 27.6 | 102.4 ± 22.8 | 84.9 ± 25.4 | 86.5 ± 27.0 | 80.0 ± 19.3 | 87.3 ± 24.0 b
PMID 29696241 · one of two readings recorded this
LDL cholesterol
increases
LDL cholesterol, mg/dL | 101.5 ± 27.3 | 101.3 ± 22.8 | 103.0 ± 27.6 | 102.4 ± 22.8 | 84.9 ± 25.4 | 86.5 ± 27.0 | 80.0 ± 19.3 | 87.3 ± 24.0 b
PMID 29696241 · one of two readings recorded this
LDL cholesterol
LDL cholesterol, mg/dL | 101.5 ± 27.3 | 101.3 ± 22.8 | 103.0 ± 27.6 | 102.4 ± 22.8 | 84.9 ± 25.4 | 86.5 ± 27.0 | 80.0 ± 19.3 | 87.3 ± 24.0 b
PMID 29696241 · one of two readings recorded this
LDL cholesterol
no effect
LDL cholesterol, mg/dL | 93.6 ± 27.6 | 94.3 ± 25.9 | 91.4 ± 26.4 | 94.8 ± 24.6
PMID 29696241 · one of two readings recorded this
LDL cholesterol
no effect
LDL cholesterol, mg/dL | 93.6 ± 27.6 | 94.3 ± 25.9 | 91.4 ± 26.4 | 94.8 ± 24.6
PMID 29696241 · one of two readings recorded this
Triglycerides
no effect
Triglycerides, mg/dL | 107.0 [83.0–143.0] | 107.0 [79.0–153.0] | 107.0 [74.0–148.0] | 111.0 [78.0–149.0]
PMID 29696241 · one of two readings recorded this
Triglycerides
no effect
Triglycerides, mg/dL | 107.0 [83.0–143.0] | 107.0 [79.0–153.0] | 107.0 [74.0–148.0] | 111.0 [78.0–149.0]
PMID 29696241 · one of two readings recorded this
Albuminuria
no effect
Albuminuria, μg/min | 8.0 [3.7–44.5] | 8.5 [3.5–39.5] | 9.0 [4.2–35.5] | 11.4 [3.6–45.2]
PMID 29696241 · one of two readings recorded this
Albuminuria
no effect
Albuminuria, μg/min | 8.0 [3.7–44.5] | 8.5 [3.5–39.5] | 9.0 [4.2–35.5] | 11.4 [3.6–45.2]
PMID 29696241 · one of two readings recorded this
Body weight
Weight, kg | 83.0 ± 14.4 | 83.1 ± 14.8 | 84.6 ± 15.5 | 84.4 ± 15.6
PMID 29696241 · one of two readings recorded this
Body weight
Weight, kg | 83.0 ± 14.4 | 83.1 ± 14.8 | 84.6 ± 15.5 | 84.4 ± 15.6
PMID 29696241 · one of two readings recorded this
Diastolic blood pressure
no effect, p = 0.8994
Overall, the effect of ALC on DBP was not significantly different from that of placebo (P = 0.8994)
PMID 29696241 · one of two readings recorded this
Diastolic blood pressure
DBP, mm Hg | 78.8 ± 6.6 | 77.4 ± 7.4 | 78.8 ± 10.3 | 78.7 ± 9.9 | 81.2 ± 6.6 | 79.5 ± 7.5 | 79.9 ± 9.7 | 77.8 ± 8.3
PMID 29696241 · one of two readings recorded this
Diastolic blood pressure
DBP, mm Hg | 78.8 ± 6.6 | 77.4 ± 7.4 | 78.8 ± 10.3 | 78.7 ± 9.9 | 81.2 ± 6.6 | 79.5 ± 7.5 | 79.9 ± 9.7 | 77.8 ± 8.3
PMID 29696241 · one of two readings recorded this
Diastolic blood pressure
DBP, mm Hg | 78.8 ± 6.6 | 77.4 ± 7.4 | 78.8 ± 10.3 | 78.7 ± 9.9 | 81.2 ± 6.6 | 79.5 ± 7.5 | 79.9 ± 9.7 | 77.8 ± 8.3
PMID 29696241 · one of two readings recorded this
Diastolic blood pressure
DBP, mm Hg | 78.8 ± 6.6 | 77.4 ± 7.4 | 78.8 ± 10.3 | 78.7 ± 9.9 | 81.2 ± 6.6 | 79.5 ± 7.5 | 79.9 ± 9.7 | 77.8 ± 8.3
PMID 29696241 · one of two readings recorded this
Diastolic blood pressure
decreases, p = 0.0387
whereas DBP was significantly reduced after 6 months of ALC (from 79.9 ± 6.7 to 78.4 ± 7.5; P = 0.0387)
PMID 29696241 · one of two readings recorded this
Diastolic blood pressure
no effect
DBP, mm Hg | 79.9 ± 6.7 | 78.4 ± 7.5 a | 79.4 ± 10.0 | 78.2 ± 9.1
PMID 29696241 · one of two readings recorded this
glomerular filtration rate by iohexol plasma clearance, and albuminuria by overnight rate nephelometry
no effect
Not recorded as a finding: sentence is a within-arm statement ('neither ALC nor placebo significantly affected'); measured GFR is not an eGFR from an equation, albuminuria in ug/min is not matched to a node requirement here
Throughout the study neither ALC nor placebo significantly affected kidney function (including directly measured GFR) and albuminuria (Table 2).
PMID 29696241 · one of two readings recorded this
Glomerular filtration rate
no effect
GFR, mL/min/1.73 m2 d | 97.2 ± 22.1 | 96.4 ± 22.4 | 101.3 ± 27.0 | 99.8 ± 26.1
PMID 29696241 · one of two readings recorded this
Glomerular filtration rate
no effect
GFR, mL/min/1.73 m2 d | 97.2 ± 22.1 | 96.4 ± 22.4 | 101.3 ± 27.0 | 99.8 ± 26.1
PMID 29696241 · one of two readings recorded this
Glucose disposal rate
no effect
Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2)
PMID 29696241 · one of two readings recorded this
Glucose disposal rate
GDR, mg/kg/min c | 5.7 [4.2–8.4] | 5.5 [4.9–7.2] | 5.7 [4.6–7.2] | 6.0 [4.9–7.6]
PMID 29696241 · one of two readings recorded this
Glucose disposal rate
GDR, mg/kg/min c | 5.7 [4.2–8.4] | 5.5 [4.9–7.2] | 5.7 [4.6–7.2] | 6.0 [4.9–7.6]
PMID 29696241 · one of two readings recorded this
HbA1c (HPLC) and HOMA-IR, between-arm comparison
no effect
Not recorded as a finding: the only between-arm sentence is agentless ('the two treatments') and does not name ALC; rule 1
Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2).
PMID 29696241 · one of two readings recorded this
HbA1c, HPLC, between-arm change at 6 months
no effect
Not recorded as a finding: the only between-arm sentence says 'the two treatments' and never names ALC (rule 1: sentence must name the compound)
Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2).
PMID 29696241 · one of two readings recorded this
HbA1c (mmol/mol)
increases, p = 0.0007
from 51.1 ± 14.0 mmol/mol to 54.4 ± 15.2 mmol/mol (P = 0.0007) and from 50.5 ± 12.2 mmol/mol to 53.0 ± 14.0 mmol/mol (P = 0.0230)
PMID 29696241 · one of two readings recorded this
HbA1c (mmol/mol)
increases, p = 0.023
from 51.1 ± 14.0 mmol/mol to 54.4 ± 15.2 mmol/mol (P = 0.0007) and from 50.5 ± 12.2 mmol/mol to 53.0 ± 14.0 mmol/mol (P = 0.0230)
PMID 29696241 · one of two readings recorded this
HbA1c
no effect
Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2)
PMID 29696241 · one of two readings recorded this
HbA1c (%)
increases
HbA1c, % | 7.0 ± 1.18 | 7.1 ± 1.19 | 7.0 ± 1.16 | 7.0 ± 1.45 | 6.6 ± 1.36 | 7.2 ± 1.58 b | 6.6 ± 1.05 | 7.0 ± 1.10 b
PMID 29696241 · one of two readings recorded this
HbA1c (%)
HbA1c, % | 7.0 ± 1.18 | 7.1 ± 1.19 | 7.0 ± 1.16 | 7.0 ± 1.45 | 6.6 ± 1.36 | 7.2 ± 1.58 b | 6.6 ± 1.05 | 7.0 ± 1.10 b
PMID 29696241 · one of two readings recorded this
HbA1c (%)
increases
HbA1c, % | 7.0 ± 1.18 | 7.1 ± 1.19 | 7.0 ± 1.16 | 7.0 ± 1.45 | 6.6 ± 1.36 | 7.2 ± 1.58 b | 6.6 ± 1.05 | 7.0 ± 1.10 b
PMID 29696241 · one of two readings recorded this
HbA1c (%)
HbA1c, % | 7.0 ± 1.18 | 7.1 ± 1.19 | 7.0 ± 1.16 | 7.0 ± 1.45 | 6.6 ± 1.36 | 7.2 ± 1.58 b | 6.6 ± 1.05 | 7.0 ± 1.10 b
PMID 29696241 · one of two readings recorded this
HbA1c (%)
HbA1c, % | 6.8 ± 1.28 | 7.1 ± 1.39 b | 6.8 ± 1.12 | 7.0 ± 1.28 a
PMID 29696241 · one of two readings recorded this
HbA1c (%)
HbA1c, % | 6.8 ± 1.28 | 7.1 ± 1.39 b | 6.8 ± 1.12 | 7.0 ± 1.28 a
PMID 29696241 · one of two readings recorded this
HOMA-IR, fasting glucose (mg/dL) times insulin (uIU/mL) over 405
no effect
Not recorded as a finding: the only between-arm sentence says 'the two treatments' and never names ALC
Overall, GDR, HbA1c, and HOMA-IR did not significantly differ between the two treatments (Table 2).
PMID 29696241 · one of two readings recorded this
Insulin
Insulin, µIU/mL | 8.7 [6.4–14.5] | 7.8 [5.4–12.4] | 8.9 [6.0–14.6] | 8.5 [5.4–14.2]
PMID 29696241 · one of two readings recorded this
Insulin
Insulin, µIU/mL | 8.7 [6.4–14.5] | 7.8 [5.4–12.4] | 8.9 [6.0–14.6] | 8.5 [5.4–14.2]
PMID 29696241 · one of two readings recorded this
lipoprotein(a), nephelometry
no effect
Not recorded as a finding: no outcome node for lipoprotein(a)
The effect of ALC on triglycerides, lipoprotein(a), LDL, HDL, and total cholesterol was not significantly different from that of placebo.
PMID 29696241 · one of two readings recorded this
Lipoprotein(a)
no effect
Lipoprotein(a), µIU/mL | 8.9 [3.7–35.0] | 9.0 [3.0–44.2] | 11.5 [3.6–28.7] | 11.3 [4.3–32.5]
PMID 29696241 · one of two readings recorded this
Lipoprotein(a)
no effect
Lipoprotein(a), µIU/mL | 8.9 [3.7–35.0] | 9.0 [3.0–44.2] | 11.5 [3.6–28.7] | 11.3 [4.3–32.5]
PMID 29696241 · one of two readings recorded this
Mean blood pressure
Mean BP, mm Hg | 98.4 ± 7.5 | 96.7 ± 7.7 a | 98.9 ± 11.1 | 97.0 ± 9.8 a
PMID 29696241 · one of two readings recorded this
Mean blood pressure
Mean BP, mm Hg | 98.4 ± 7.5 | 96.7 ± 7.7 a | 98.9 ± 11.1 | 97.0 ± 9.8 a
PMID 29696241 · one of two readings recorded this
overnight urinary albumin excretion, rate nephelometry; GFR by iohexol plasma clearance
no effect
Not recorded as a finding: the sentence reports 'neither ALC nor placebo' affected them, a within-arm statement, not a between-arm contrast; GFR was measured, not estimated, so the egfr node does not fit
Throughout the study neither ALC nor placebo significantly affected kidney function (including directly measured GFR) and albuminuria (Table 2).
PMID 29696241 · one of two readings recorded this
Serum creatinine
no effect
Serum creatinine, mg/dL | 0.93 ± 0.2 | 0.93 ± 0.2 | 0.94 ± 0.2 | 0.95 ± 0.2
PMID 29696241 · one of two readings recorded this
Serum creatinine
no effect
Serum creatinine, mg/dL | 0.93 ± 0.2 | 0.93 ± 0.2 | 0.94 ± 0.2 | 0.95 ± 0.2
PMID 29696241 · one of two readings recorded this
Serum glucose
Serum glucose | 147.2 ± 41.7 | 144.0 ± 42.1 | 155.0 ± 42.1 | 146.5 ± 46.2
PMID 29696241 · one of two readings recorded this
Serum glucose
Serum glucose | 147.2 ± 41.7 | 144.0 ± 42.1 | 155.0 ± 42.1 | 146.5 ± 46.2
PMID 29696241 · one of two readings recorded this
Systolic blood pressure
no effect, p = 0.9539
SBP was not significantly different after 6 months of treatment with ALC or placebo, even after adjustment for baseline values (P = 0.9539)
PMID 29696241 · one of two readings recorded this
Systolic blood pressure
SBP, mm Hg | 136.2 ± 13.0 | 134. 0 ± 13.7 | 138.6 ± 19.3 | 135.8 ± 16.4 | 134.6 ± 14.9 | 132.6 ± 13.9 | 137.6 ± 17.4 | 133.2 ± 13.6 a
PMID 29696241 · one of two readings recorded this
Systolic blood pressure
SBP, mm Hg | 136.2 ± 13.0 | 134. 0 ± 13.7 | 138.6 ± 19.3 | 135.8 ± 16.4 | 134.6 ± 14.9 | 132.6 ± 13.9 | 137.6 ± 17.4 | 133.2 ± 13.6 a
PMID 29696241 · one of two readings recorded this
Systolic blood pressure
decreases, p = 0.015
in the short-term statin therapy, SBP significantly decreased only when patients took placebo (137.6 ± 17.4 mm Hg to 133.2 ± 13.6 mm Hg; P = 0.015)
PMID 29696241 · one of two readings recorded this
Systolic blood pressure
SBP, mm Hg | 136.2 ± 13.0 | 134. 0 ± 13.7 | 138.6 ± 19.3 | 135.8 ± 16.4 | 134.6 ± 14.9 | 132.6 ± 13.9 | 137.6 ± 17.4 | 133.2 ± 13.6 a
PMID 29696241 · one of two readings recorded this
Systolic blood pressure
no effect
SBP, mm Hg | 135.4 ± 13.9 | 133.3 ± 13.7 | 138.1 ± 18.3 | 134.5 ± 15.1 a
PMID 29696241 · one of two readings recorded this
Systolic blood pressure
decreases, p = 0.0187
it significantly decreased in patients allocated to placebo (from 138.1 ± 18.3 mm Hg to 134.5 ± 15.1 mm Hg; P = 0.0187)
PMID 29696241 · one of two readings recorded this
Total cholesterol
Total cholesterol, mg/dL | 167.9 ± 32.4 | 168.8 ± 30.2 | 170.7 ± 35.7 | 171.3 ± 32.4 | 148.4 ± 27.8 | 151.8 ± 30.4 | 141.0 ± 24.0 | 151.3 ± 27.6 b
PMID 29696241 · one of two readings recorded this
Total cholesterol
Total cholesterol, mg/dL | 167.9 ± 32.4 | 168.8 ± 30.2 | 170.7 ± 35.7 | 171.3 ± 32.4 | 148.4 ± 27.8 | 151.8 ± 30.4 | 141.0 ± 24.0 | 151.3 ± 27.6 b
PMID 29696241 · one of two readings recorded this
Total cholesterol
increases
Total cholesterol, mg/dL | 167.9 ± 32.4 | 168.8 ± 30.2 | 170.7 ± 35.7 | 171.3 ± 32.4 | 148.4 ± 27.8 | 151.8 ± 30.4 | 141.0 ± 24.0 | 151.3 ± 27.6 b
PMID 29696241 · one of two readings recorded this
Total cholesterol
Total cholesterol, mg/dL | 167.9 ± 32.4 | 168.8 ± 30.2 | 170.7 ± 35.7 | 171.3 ± 32.4 | 148.4 ± 27.8 | 151.8 ± 30.4 | 141.0 ± 24.0 | 151.3 ± 27.6 b
PMID 29696241 · one of two readings recorded this
Total cholesterol
no effect
Total cholesterol, mg/dL | 158.6 ± 31.7 | 160.7 ± 31.2 | 155.7 ± 33.7 | 161.3 ± 31.6 a
PMID 29696241 · one of two readings recorded this
Total cholesterol
increases, p = 0.0164
total and HDL cholesterol significantly increased and decreased from 155.7 ± 33.7 mg/dL to 161.3 ± 31.6 mg/dL (P = 0.0164) and from 44.9 ± 12.0 mg/dL to 43.3 ± 12.4 mg/dL (P = 0.0174)
PMID 29696241 · one of two readings recorded this
adverse events, proportion of patients with any adverse event
13.3% ALC vs 7.7% placebo
Not recorded as a finding: supplement-adverse-event-incidence node requires event proportion; the sentence gives two proportions with no between-arm test or two-sided statement
The proportion of patients with AE was 13.3% in ALC-treated group, and 7.7% in placebo-treated group respectively (Table 5).
PMID 30906386 · one of two readings recorded this
CDR-SB
unclear, p = 0.029
CDR-SB | 0.029†
PMID 30906386 · one of two readings recorded this
CDR-SB
ALC | 4.7±1.2 | 4.6±1.1 | 4.2±1.3
PMID 30906386 · one of two readings recorded this
CDR-SB
ALC | 4.7±1.2 | 4.6±1.1 | 4.2±1.3
PMID 30906386 · one of two readings recorded this
CDR-SB
Placebo | 4.7±1.2 | 4.5±0.9 | 4.4±1.2
PMID 30906386 · one of two readings recorded this
CDR-SB
Placebo | 4.7±1.2 | 4.5±0.9 | 4.4±1.2
PMID 30906386 · one of two readings recorded this
Clinical Dementia Rating Sum of Boxes (CDR-SB), global clinical rating
no effect
Not recorded as a finding: no_outcome_node: no CDR-SB node in the outcome list
Global cognitive impression scales such as CDR, and CDR-SB also showed non-significant changes between ALC- and placebo-treated groups (Table 2).
PMID 30906386 · one of two readings recorded this
COWAT
no effect, p = 0.403
COWAT | 0.403
PMID 30906386 · one of two readings recorded this
COWAT
ALC | 34.5±13.0 | 35.5±15.1 | 37.6±15.3
PMID 30906386 · one of two readings recorded this
COWAT
ALC | 34.5±13.0 | 35.5±15.1 | 37.6±15.3
PMID 30906386 · one of two readings recorded this
COWAT
Placebo | 31.4±10.0 | 34.6±14.0 | 33.8±15.3
PMID 30906386 · one of two readings recorded this
COWAT
Placebo | 31.4±10.0 | 34.6±14.0 | 33.8±15.3
PMID 30906386 · one of two readings recorded this
CWST color correct
no effect, p = 0.85
CWST color correct | 0.850
PMID 30906386 · one of two readings recorded this
CWST color correct
ALC | 97.5±33.6 | 97.9±32.0 | 97.9±32.3
PMID 30906386 · one of two readings recorded this
CWST color correct
ALC | 97.5±33.6 | 97.9±32.0 | 97.9±32.3
PMID 30906386 · one of two readings recorded this
CWST color correct
Placebo | 94.1±35.4 | 93.2±34.7 | 94.1±32.3
PMID 30906386 · one of two readings recorded this
CWST color correct
Placebo | 94.1±35.4 | 93.2±34.7 | 94.1±32.3
PMID 30906386 · one of two readings recorded this
CWST color incorrect
no effect, p = 0.302
CWST color incorrect | 0.302
PMID 30906386 · one of two readings recorded this
CWST color incorrect
ALC | 13.1±25.5 | 12.3±20.9 | 14.1±21.4
PMID 30906386 · one of two readings recorded this
CWST color incorrect
ALC | 13.1±25.5 | 12.3±20.9 | 14.1±21.4
PMID 30906386 · one of two readings recorded this
CWST color incorrect
Placebo | 20.4±26.8 | 20.6±25.4 | 19.6±28.0
PMID 30906386 · one of two readings recorded this
CWST color incorrect
Placebo | 20.4±26.8 | 20.6±25.4 | 19.6±28.0
PMID 30906386 · one of two readings recorded this
CWST word correct
no effect, p = 0.732
CWST word correct | 0.732
PMID 30906386 · one of two readings recorded this
CWST word correct
ALC | 107.9±15.5 | 108.1±14.0 | 109.6±12.4
PMID 30906386 · one of two readings recorded this
CWST word correct
ALC | 107.9±15.5 | 108.1±14.0 | 109.6±12.4
PMID 30906386 · one of two readings recorded this
CWST word correct
Placebo | 100.7±15.5 | 100.9±27.6 | 100.7±28.0
PMID 30906386 · one of two readings recorded this
CWST word correct
Placebo | 100.7±15.5 | 100.9±27.6 | 100.7±28.0
PMID 30906386 · one of two readings recorded this
CWST word incorrect
no effect, p = 0.753
CWST word incorrect | 0.753
PMID 30906386 · one of two readings recorded this
CWST word incorrect
ALC | 3.3±10.0 | 3.9±9.9 | 3.4±11.4
PMID 30906386 · one of two readings recorded this
CWST word incorrect
ALC | 3.3±10.0 | 3.9±9.9 | 3.4±11.4
PMID 30906386 · one of two readings recorded this
CWST word incorrect
Placebo | 12.7±16.8 | 12.3±20.4 | 11.7±28.0
PMID 30906386 · one of two readings recorded this
CWST word incorrect
Placebo | 12.7±16.8 | 12.3±20.4 | 11.7±28.0
PMID 30906386 · one of two readings recorded this
GDS
no effect, p = 0.973
GDS | 0.973
PMID 30906386 · one of two readings recorded this
GDS
ALC | 12.8±5.4 | 13.9±5.1 | 13.6±5.1
PMID 30906386 · one of two readings recorded this
GDS
ALC | 12.8±5.4 | 13.9±5.1 | 13.6±5.1
PMID 30906386 · one of two readings recorded this
GDS
Placebo | 13.8±5.1 | 14.7±5.7 | 14.5±5.2
PMID 30906386 · one of two readings recorded this
GDS
Placebo | 13.8±5.1 | 14.7±5.7 | 14.5±5.2
PMID 30906386 · one of two readings recorded this
Geriatric Depression Scale (GDS) score
no effect
Not recorded as a finding: no_outcome_node: no Geriatric Depression Scale node in the outcome list
Cognitive assessment tools such as K-MMSE, K-CWST, COWAT, K-TMT-E, and GDS, K-IADL showed no significant differences between ALC- and placebo-treated groups (Tables 2 and 4).
PMID 30906386 · one of two readings recorded this
K-IADL
unclear, p = 0.003
K-IADL | 0.003†
PMID 30906386 · one of two readings recorded this
K-IADL
ALC | 10.7±5.1 | 10.6±10.2 | 9.7±9.6
PMID 30906386 · one of two readings recorded this
K-IADL
ALC | 10.7±5.1 | 10.6±10.2 | 9.7±9.6
PMID 30906386 · one of two readings recorded this
K-IADL
Placebo | 13.5±6.9 | 9.6±7.0 | 9.3±10.1
PMID 30906386 · one of two readings recorded this
K-IADL
Placebo | 13.5±6.9 | 9.6±7.0 | 9.3±10.1
PMID 30906386 · one of two readings recorded this
K-MMSE
no effect, p = 0.819
K-MMSE | 0.819
PMID 30906386 · one of two readings recorded this
K-MMSE
ALC | 21.5±2.7 | 21.6±3.5 | 21.6±3.6
PMID 30906386 · one of two readings recorded this
K-MMSE
ALC | 21.5±2.7 | 21.6±3.5 | 21.6±3.6
PMID 30906386 · one of two readings recorded this
K-MMSE
Placebo | 21.1±2.4 | 21.1±2.7 | 21.1±2.9
PMID 30906386 · one of two readings recorded this
K-MMSE
Placebo | 21.1±2.4 | 21.1±2.7 | 21.1±2.9
PMID 30906386 · one of two readings recorded this
K-TMT-E status
no effect, p = 0.117
ALC | 0.117
PMID 30906386 · one of two readings recorded this
MoCA-K abstract sub-item
no effect, p = 0.443
Abstract | 0.443
PMID 30906386 · one of two readings recorded this
MoCA-K abstract sub-item
ALC | 0.8±0.6 | 0.9±0.8 | 0.9±0.6
PMID 30906386 · one of two readings recorded this
MoCA-K abstract sub-item
ALC | 0.8±0.6 | 0.9±0.8 | 0.9±0.6
PMID 30906386 · one of two readings recorded this
MoCA-K abstract sub-item
Placebo | 0.8±0.7 | 0.8±0.7 | 1.1±0.6
PMID 30906386 · one of two readings recorded this
MoCA-K abstract sub-item
Placebo | 0.8±0.7 | 0.8±0.7 | 1.1±0.6
PMID 30906386 · one of two readings recorded this
MoCA-K attention sub-item
unclear, p = 0.025
Attention* | 0.025
PMID 30906386 · one of two readings recorded this
MoCA-K attention sub-item
ALC | 3.7±1.4 | 3.7±1.1 | 3.5±1.5
PMID 30906386 · one of two readings recorded this
MoCA-K attention sub-item
ALC | 3.7±1.4 | 3.7±1.1 | 3.5±1.5
PMID 30906386 · one of two readings recorded this
MoCA-K attention sub-item
Placebo | 4.1±1.7 | 3.5±1.3 | 3.3±1.3
PMID 30906386 · one of two readings recorded this
MoCA-K attention sub-item
Placebo | 4.1±1.7 | 3.5±1.3 | 3.3±1.3
PMID 30906386 · one of two readings recorded this
MoCA-K delayed recall sub-item
no effect, p = 0.1
Delayed recall | 0.100
PMID 30906386 · one of two readings recorded this
MoCA-K delayed recall sub-item
ALC | 0.9±0.9 | 1.1±0.7 | 1.3±0.8
PMID 30906386 · one of two readings recorded this
MoCA-K delayed recall sub-item
ALC | 0.9±0.9 | 1.1±0.7 | 1.3±0.8
PMID 30906386 · one of two readings recorded this
MoCA-K delayed recall sub-item
Placebo | 1.2±1.0 | 1.2±0.9 | 1.2±0.9
PMID 30906386 · one of two readings recorded this
MoCA-K delayed recall sub-item
Placebo | 1.2±1.0 | 1.2±0.9 | 1.2±0.9
PMID 30906386 · one of two readings recorded this
MoCA-K language sub-item
increases, p = 0.012
Language* | 0.012
PMID 30906386 · one of two readings recorded this
MoCA-K language sub-item
ALC | 1.4±0.9 | 1.5±1.0 | 1.9±0.8
PMID 30906386 · one of two readings recorded this
MoCA-K language sub-item
ALC | 1.4±0.9 | 1.5±1.0 | 1.9±0.8
PMID 30906386 · one of two readings recorded this
MoCA-K language sub-item
Placebo | 1.3±0.8 | 1.8±1.0 | 1.5±0.7
PMID 30906386 · one of two readings recorded this
MoCA-K language sub-item
Placebo | 1.3±0.8 | 1.8±1.0 | 1.5±0.7
PMID 30906386 · one of two readings recorded this
MoCA-K naming sub-item
no effect, p = 0.31
Naming | 0.310
PMID 30906386 · one of two readings recorded this
MoCA-K naming sub-item
ALC | 2.5±0.7 | 2.5±0.8 | 2.5±0.8
PMID 30906386 · one of two readings recorded this
MoCA-K naming sub-item
ALC | 2.5±0.7 | 2.5±0.8 | 2.5±0.8
PMID 30906386 · one of two readings recorded this
MoCA-K naming sub-item
Placebo | 2.4±1.0 | 2.2±1.1 | 2.3±1.1
PMID 30906386 · one of two readings recorded this
MoCA-K naming sub-item
Placebo | 2.4±1.0 | 2.2±1.1 | 2.3±1.1
PMID 30906386 · one of two readings recorded this
MoCA-K orientation sub-item
unclear
Orientation† | 0.000
PMID 30906386 · one of two readings recorded this
MoCA-K orientation sub-item
ALC | 4.7±1.4 | 4.2±1.5 | 4.1±1.3
PMID 30906386 · one of two readings recorded this
MoCA-K orientation sub-item
ALC | 4.7±1.4 | 4.2±1.5 | 4.1±1.3
PMID 30906386 · one of two readings recorded this
MoCA-K orientation sub-item
Placebo | 4.3±1.3 | 4.0±1.4 | 3.8±1.3
PMID 30906386 · one of two readings recorded this
MoCA-K orientation sub-item
Placebo | 4.3±1.3 | 4.0±1.4 | 3.8±1.3
PMID 30906386 · one of two readings recorded this
MoCA-K total
increases, p = 0.01
MoCA-K | 0.010*
PMID 30906386 · one of two readings recorded this
MoCA-K total
ALC | 17.3±4.1 | 17.2±4.0 | 17.6±4.2
PMID 30906386 · one of two readings recorded this
MoCA-K total
ALC | 17.3±4.1 | 17.2±4.0 | 17.6±4.2
PMID 30906386 · one of two readings recorded this
MoCA-K total
Placebo | 16.7±3.8 | 16.3±3.1 | 15.9±3.8
PMID 30906386 · one of two readings recorded this
MoCA-K total
Placebo | 16.7±3.8 | 16.3±3.1 | 15.9±3.8
PMID 30906386 · one of two readings recorded this
MoCA-K visuospatial sub-item
no effect, p = 0.565
Visuospatial | 0.565
PMID 30906386 · one of two readings recorded this
MoCA-K visuospatial sub-item
ALC | 2.8±1.4 | 2.9±1.4 | 3.0±1.3
PMID 30906386 · one of two readings recorded this
MoCA-K visuospatial sub-item
ALC | 2.8±1.4 | 2.9±1.4 | 3.0±1.3
PMID 30906386 · one of two readings recorded this
MoCA-K visuospatial sub-item
Placebo | 2.3±1.4 | 2.4±1.3 | 2.4±1.3
PMID 30906386 · one of two readings recorded this
MoCA-K visuospatial sub-item
Placebo | 2.3±1.4 | 2.4±1.3 | 2.4±1.3
PMID 30906386 · one of two readings recorded this
proportion of patients with any adverse event, tallied from the trial's AE records
Not recorded as a finding: no direction word and no between-arm test in the sentence; supplement-adverse-event-incidence needs a stated direction
The proportion of patients with AE was 13.3% in ALC-treated group, and 7.7% in placebo-treated group respectively (Table 5).
PMID 30906386 · one of two readings recorded this